Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01894373

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Psoriasis

Sponsor: Chinese PLA General Hospital

Conditions Adoptive Immunotherapy Psoriasis

Interventions Adoptive Immunotherapy CIK

Updated 5 times since 2017 Last updated: May 13, 2018 Started: Jun 30, 2015 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01894373, this PHASE1/PHASE2 trial focuses on Adoptive Immunotherapy and Psoriasis and remains completed. Sponsored by Chinese PLA General Hospital, it has been updated 5 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China